Verona Pharma (NASDAQ:TARA) and Enzon Pharmaceuticals (OTCMKTS:ENZN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

Verona Pharma has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Enzon Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.

Valuation and Earnings

This table compares Verona Pharma and Enzon Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Verona Pharma N/A N/A -$14.99 million N/A N/A
Enzon Pharmaceuticals $210,000.00 37.08 -$980,000.00 N/A N/A

Enzon Pharmaceuticals has higher revenue and earnings than Verona Pharma.

Analyst Recommendations

This is a breakdown of recent recommendations for Verona Pharma and Enzon Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verona Pharma 0 0 2 0 3.00
Enzon Pharmaceuticals 0 0 0 0 N/A

Verona Pharma currently has a consensus price target of $50.00, suggesting a potential upside of 157.20%. Given Verona Pharma’s higher possible upside, equities analysts plainly believe Verona Pharma is more favorable than Enzon Pharmaceuticals.

Insider and Institutional Ownership

67.7% of Verona Pharma shares are held by institutional investors. 45.7% of Verona Pharma shares are held by company insiders. Comparatively, 0.1% of Enzon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Verona Pharma and Enzon Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Verona Pharma N/A -118.18% -77.97%
Enzon Pharmaceuticals -1,745.90% -17.93% -13.84%


Verona Pharma beats Enzon Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Verona Pharma Company Profile

ArTara Therapeutics, Inc. develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with's FREE daily email newsletter.